Regulus Therapeutics reported $-6718000 in Pre-Tax Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Alnylam Pharmaceuticals ALNY:US $ -274.67M 35.32M
Biogen BIIB:US $ 874.8M 28.6M
Celldex Therapeutics CLDX:US $ -36M 12.95M
Intercept Pharmaceuticals ICPT:US $ -20.32M 3.04M
Intrexon XON:US $ -26.15M 6.84M
Lexicon Pharmaceuticals LXRX:US $ -24587000 1.11M
Omeros OMER:US $ -39494000 7.82M
Regulus Therapeutics RGLS:US $ -6.72M 0.42M
Sangamo Biosciences SGMO:US $ -43.09M 0.83M
Spectrum Pharmaceuticals SPPI:US $ -15.39M 24.37M
Takeda 4502:JP Y 155473M 209520M
Vital Therapies VTL:US $ -21.9M 1.09M